A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies, Followed by an Expansion in Subjects With Measurable Disease

Trial Profile

A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies, Followed by an Expansion in Subjects With Measurable Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Sapanisertib (Primary)
  • Indications Bladder cancer; Endometrial cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 03 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 07 Sep 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top